The need for effective radiosentitizing agents: Experience in patients with complete pathological response

Anti-Cancer Drugs

Volumn 22, Issue 4, 2011, Pages 308-310

  Habr Gama, Angelita ^a,b,c   Perez, Rodrigo O ^a,b,c   São Julião, Guilherme P ^a,b   Proscurshim, Igor ^a,b   Gama Rodrigues, Joaquim ^b,c  

^a Department of Gastroenterology ^*  (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c Angelita and Joaquim Gama Institute   (Brazil)

Author keywords

Complete response; neoadjuvant therapy; radiosensitizing agents; rectal cancer; tumor response

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; RADIOSENSITIZING AGENT;

CANCER CONTROL; CANCER SURVIVAL; CHEMORADIOTHERAPY; HUMAN; PRIORITY JOURNAL; RECTUM CANCER; REVIEW; TREATMENT OUTCOME; TUMOR REGRESSION; UNSPECIFIED SIDE EFFECT;

HUMANS; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; RADIATION-SENSITIZING AGENTS; RECTAL NEOPLASMS;

EID: 79952988762     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e3283428193     Document Type: Review

References (20)

1. Colquhoun P, Wexner SD, Cohen A. Adjuvant therapy is valuable in the treatment of rectal cancer despite total mesorectal excision. J Surg Oncol 2003;83:133-139. (Pubitemid 36807940)
2. Heald RJ, Ryall R. Recurrent cancer after restorative resection of the rectum. Br Med J (Clin Res Ed) 1982;284:826-827.
3. Simunovic M, Sexton R, Rempel E. Optimal preoperative assessment and surgery for rectal cancer may greatly limit the need for radiotherapy. Br J Surg 2003;90:999-1003. (Pubitemid 37026331)
4. Tjandra JJ, Kilkenny JW, Buie WD. Practice parameters for the management of rectal cancer (revised). Dis Colon Rectum 2005;48:411-423. (Pubitemid 40767859)
5. Sauer R, Becker H, Hohenberger W. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004;351:1731-1740.
6. Pucciarelli S, Capirci C, Emanuele U. Relationship between pathologic T-stage and nodal metastasis after preoperative chemoradiotherapy for locally advanced rectal cancer. Ann Surg Oncol 2005;12:111-116. (Pubitemid 40486618)
7. Maas M, Nelemans PJ, Valentini V. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol 2010;11:835-844.
8. Bujko K, Nowacki MP, Nasierowska-Guttmejer A. Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg 2006;93:1215-1223. (Pubitemid 44547018)
9. Tulchinsky H, Shmueli E, Figer A. An interval >7 weeks between neoadjuvant therapy and surgery improves pathologic complete response and disease-free survival in patients with locally advanced rectal cancer. Ann Surg Oncol 2008;15:2661-2667.
10. Kalady MF, De Campos-Lobato LF, Stocchi L. Predictive factors of pathologic complete response after neoadjuvant chemoradiation for rectal cancer. Ann Surg 2009;250:582-589.
11. Kerr SF, Norton S, Glynne-Jones R. Delaying surgery after neoadjuvant chemoradiotherapy for rectal cancer may reduce postoperative morbidity without compromising prognosis. Br J Surg 2008;95:1534-1540.
12. Radu C, Berglund A, Pahlman L. Short-course preoperative radiotherapy with delayed surgery in rectal cancer-a retrospective study. Radiother Oncol 2008;87:343-349.
13. Bosset JF, Calais G, Mineur L. Enhanced tumorocidal effect of chemotherapy with preoperative radiotherapy for rectal cancer: preliminary results-EORTC 22921. J Clin Oncol 2005;23:5620-5627.
14. Bosset JF, Collette L, Calais G. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 2006;355:1114-1123. (Pubitemid 44394918)
15. Sanghera P, Wong DW, McConkey CC. Chemoradiotherapy for rectal cancer: an updated analysis of factors affecting pathological response. Clin Oncol (R Coll Radiol) 2008;20:176-183.
16. Ben-Josef E. Capecitabine and radiotherapy as neoadjuvant treatment for rectal cancer. Am J Clin Oncol 2007;30:649-655. (Pubitemid 350307192)
17. Gerard JP, Azria D, Gourgou-Bourgade S. Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2. J Clin Oncol 2010;28:1638-1644.
18. Weiss C, Arnold D, Dellas K. Preoperative radiotherapy of advanced rectal cancer with capecitabine and oxaliplatin with or without cetuximab: a pooled analysis of three prospective phase I-II trials. Int J Radiat Oncol Biol Phys 2010;78:472-478.
19. Glynne-Jones R, Mawdsley S, Harrison M. Cetuximab and chemoradiation for rectal cancer: is the water getting muddy? Acta Oncol 2010;49:278-286.
20. Habr-Gama A, Perez RO, Sabbaga J. Increasing the rates of complete response to neoadjuvant chemoradiotherapy for distal rectal cancer: results of a prospective study using additional chemotherapy during the resting period. Dis Colon Rectum 2009;52:1927-1934.